The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $647,782 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the San Diego Biomedical Research Institute, a non-profit organization, to evaluate the therapeutic potential of hypoxia mimetics in treating inflammatory demyelinating diseases like multiple sclerosis (MS).
The key objectives of the 5-year project are to: 1) Define an optimal treatment protocol using hypoxia mimetic drugs to accelerate recovery from the experimental autoimmune encephalomyelitis (EAE) animal model of MS; 2) Evaluate how hypoxia-inducible factor (HIF)-mediated vascular remodeling contributes to the protective effects; and 3) Determine the role of monocyte apoptosis in the hypoxia-mediated suppression of neuroinflammation. The project aims to build on the researchers' prior finding that chronic mild hypoxia can accelerate recovery in the EAE model and that hypoxia mimetic drugs can provide similar therapeutic benefits.
Generated 2/25/25, 2:46 AM